News | September 21, 2009

GE Highlights Innovations in Molecular Imaging at WMIC

Discovery PET/CT 690

September 21, 2009 - GE Healthcare hosts two consortium workshops on imaging technologies and molecular imaging agents at the World Molecular Imaging Congress (WMIC) September 23-26, 2009, in Montreal, Canada.

At the GE Healthcare WMIC booth #302, the company will introduce new diagnostic imaging applications, GE Healthcare’s pre-clinical imaging serves the development of new therapeutics and tracers by using newest imaging technologies with animal disease models. The eXplore speCZT, the first full-ring solid-state detector small animal SPECT, focuses on high throughput and rapid dynamic imaging. The system utilizes a cadmium zinc telluride (CZT) detector with high-energy resolution to enable dual or triple radionuclide imaging. The system also has the capability to combine with the world-class CT120 X-ray CT system for seamless dual-modality imaging, and fusion. In this configuration, users can benefit from improved quantitative accuracy in measuring SPECT tracer uptake with our new SPECT/CT Attenuation Correction feature.

Understanding researcher’s multi-modality needs, the Triumph pre-clinical system, is an all digital, fully integrated molecular imaging system for biomedical research and pharmaceutical development, designed to accommodate any combination of SPECT, PET and CT.

Molecular imaging is only possible with the latest in imaging agents and radiopharmaceuticals. TRACERlab FX synthesizers are designed for the production these PET tracers. Worldwide researchers use TRACERlabs for the synthesis of common tracers and the rapid development of new PET imaging agents. GE Healthcare aims to simplify the complexity of radiopharmacy infrastructure into a single touch-point solution. TRACERcenter-GMP is a combination of equipment, information and services that allow you to establish and operate your research or clinical PET tracer production center with confidence by providing state-of-the-art instrumentation, comprehensive documentation and GMP training and consulting services to provide new centers with support and knowledge for the production of PET tracers.

The Discovery PET/CT 600 series continues to expand with the introduction of the Discovery PET/CT 690 – a molecular imaging tool designed go beyond the needs of the clinical practice and provide the necessary tools and technologies to explore the future of PET/CT imaging. With specialized detector configuration designed for sensitivity, event throughput and efficiency, researchers and clinicians have the necessary speed in workflow, protocol flexibility and unique timing resolution technology to help forge new frontiers in clinical techniques, drug discovery and motion management.

The IN Cell Analyzer 2000 is a flexible cell imaging system for High Content Analysis with excellent image quality, speed and ease-of-use for all screening and research needs. The flexibility of the system enables scientists to perform a wide variety of previously challenging experiments with a single instrument: from investigative microscopy through to automated screening, and imaging of organelles, cells, tissues and whole organisms.

In addition, GE will host workshops at WMIC. These are the following:

Innovations in Pre-Clinical Molecular Imaging (Thursday, September 24th, 5:40pm – 7:10pm): Track the molecular progression of disease and response to therapeutics over time in small animals to accelerate research. This session will explore core emerging technologies and applications through GE Healthcare's small animal molecular imaging systems in the journey to understand disease, from the beginning.

Current Topics in PET Tracer Research (Friday, September 25th, 7:30am – 9:00am) To nderstanddisease, from the beginning, molecular imaging requires the convergence of imaging agents and equipment. In this session, researchers from the academic community and from GE Healthcare will present and discuss progress in development and validation of new PET tracers.

For more information: www.gehealthcare.com

Related Content

Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Overlay Init